2014 Grants Awarded

The Rolfe Pancreatic Cancer Foundation was proud to award the following grants in 2014:

Johns Hopkins Medical Institutions (Baltimore, MD)
For Continued Support of  “Genetic Sequencing of Patients with Familial Pancreatic Cancer.”  Dr. Ralph Hruban’s pancreatic cancer team has sequenced the genomes (all 3 billion letters of DNA) of 700+ patients with familial pancreatic cancer. Dr. Nick Roberts will now analyze all the data. This project seeks to discover the genes that cause familial pancreatic cancer based on a person’s DNA sequence. 

Laura Wood, MD, PhD
 “Characterization of the Moment of Invasion in Pancreatic Neoplasms”
Invasive pancreatic cancer is an aggressive deadly cancer with a dismal prognosis. Invasive pancreatic cancer arises from non-invasive precursor lesions that, if detected early enough, are curable. The goal is to remove these lesions before they progress to an invasive cancer. This research will try to characterize the moment of transition between non-invasive cysts and the infiltrating cancer.

The University of Chicago (Chicago)
Support of a post-doctoral surgical oncology fellow, who is dedicating two years to early detection pancreatic cancer research under the supervision of Drs. Kevin Roggin and Mitchel Posner. The fellowship is named The Rolfe Pancreatic Cancer Foundation Fellow for the entire term of the gift.

Early Detection Projects via the Lustgarten Foundation
The Rolfe Foundation and the Lustgarten Foundation are partners in the annual DASH for Detection 5K. Every year we pledge a grant to Lustgarten representing 50 percent of the net proceeds from the DASH, which they then use to fund an appropriate early detection research project based on the advice of their Scientific Advisory Board. 

This year the Science Committee chose two imaging projects based on Lustgarten’s recommendations. The Science Committee decided to support two imaging projects because the Lustgarten Scientific Advisory Board believes that these will produce significant results in the near term using a method that is non-invasive.

Dr. Roger Y. Tsien from University of California (San Diego) 
This project is led by a Nobel Laureate who is the world’s leading expert on imaging agents. In this project he proposes to develop a completely new type of agent to be used with standard MRI technology that will visualize pancreatic cancers at very early stages.

Dr. Ken Olive from Columbia University (NYC)
This project uses a new imaging approach called Harmonic Motion Imaging to detect changes in tissue composition that are associated with different pancreatic disease states, and evaluate its utility for early detection and diagnosis. Dr. Olive seeks to perfect the Ultrasound and MRI technologies.

Cancer Wellness Center (Northbrook)
For continued support of their pancreatic cancer discussion group.

Wellness House (Hinsdale)
For continued support of their pancreatic cancer discussion group.